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Aims: Following a favourable pilot trial using a single bolus of ciclosporin, it has been
unclear why 2 large studies (CYCLE and CIRCUS) failed to prevent reperfusion injury
and reduce infarct size in STEMI (ST elevation myocardial infarction). The purpose of
this study was to assess the effect of ciclosporin on myocardial injury, left ventricular
remodelling and lymphocyte kinetics in patients with acute STEMI undergoing pri-
mary percutaneous coronary intervention.
Methods: In this double-blind, single centre trial, we randomly assigned 52 acute
STEMI patients with an onset of pain of <6 hours and blocked culprit artery to a sin-
gle bolus of ciclosporin (n = 26) or placebo (n = 26, control group) prior to reperfusion
by stent percutaneous coronary intervention. The primary endpoint was infarct size
at 12 weeks.
Results: Mean infarct size at 12 weeks was identical in both groups (9.1% [standard
deviation= 7.0] vs 9.1% [standard deviation = 7.0], P = .99; 95% confidence interval
for difference: −4.0 to 4.1). CD3 T-lymphocytes dropped to similar levels at
90 minutes (867 vs 852 cells/μL, control vs ciclosporin) and increased to 1454 vs
1650 cells/μL at 24 hours.
Conclusion: In our pilot trial, a single ciclosporin bolus did not affect infarct size or
left ventricular remodelling, matching the results from CYCLE and CIRCUS. Our study
suggests that ciclosporin does either not reach ischaemic cardiomyocytes, or requires
earlier application during first medical contact. Finally, 1 bolus of ciclosporin is not
sufficient to inhibit CD4 T-lymphocyte proliferation during remodelling. We there-
fore believe that further studies are warranted.
(Evaluating the effectiveness of intravenous Ciclosporin on reducing reperfusion
injury in pAtients undergoing PRImary percutaneous coronary intervention [CAPRI];
NCT02390674)
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1 | INTRODUCTION
Primary percutaneous coronary intervention (PPCI) has improved out-
comes for patients with ST-segment myocardial infarction (STEMI)
dramatically over the past years. In-hospital mortality rates in high vol-
ume centres have dropped <5%, owing to rapid reperfusion, optimal
antiplatelet therapy and latest-generation stents. However, 5-year
mortality rate in all-comers with large infarcts undergoing PPCI has
been around 20% in our centre,1 supporting the fact that adverse
remodelling and potential progression to heart failure still present an
unfulfilled clinical need.2 In preclinical models of myocardial infarction,
reperfusion itself leads to additional damage known as myocardial
ischaemia/reperfusion injury (IRI). Since mitochondria are thought to
be the critical mediator of IRI,3 drugs that target the mitochondrial
permeability transition pore (MPTP) have been tested in a multitude
of animal models.3-5 A pilot trial by Piot and colleagues demonstrated
a favourable effect of ciclosporin in patients on infarct size, estimated
by the release of creatine kinase following reperfusion.6 In addition to
its known immunosuppressive function, ciclosporin is also a potent
inhibitor of the MPTP,7 which has demonstrated a beneficial effect on
ischaemia/reperfusion injury under experimental conditions.8 How-
ever, 2 recent multicentre trials (published after the start of the CAPRI
trial) using ciclosporin prior to PPCI have failed to demonstrate a ben-
eficial effect.9,10 It has been debated whether either preclinical models
do not resemble the clinical situation, or whether there have been
inadequacies in the trial design and, more importantly, whether cardi-
oprotective therapies should continue to be pursued at all.11 A signifi-
cant drawback of the negative clinical trials targeting IRI has been the
lack of mechanistic insight into their failure. Ciclosporin is widely used
as an immunosuppressive drug to prevent organ transplant rejec-
tion.12-14 Through its intracellular binding to cyclophylin it inhibits cal-
cineurin, a serine/threonine phosphatase, and thereby inhibits various
T-cell responses,14 most importantly T-lymphocyte proliferation.15
Our recently published data also suggests depletion of circulating T-
lymphocytes in STEMI patients immediately following PPCI, consis-
tent with an early participation of T-lymphocytes in human myocardial
I-R injury,16 making lymphocytes another pharmacological target in
the treatment of STEMI.
The aim of our pilot trial was to investigate the effect of
ciclosporin on IRI and concomitantly achieve mechanistic insight by
studying its biological effects on the adaptive immune response as a
proximal readout. To avoid design-specific flaws, the CAPRI trial was
set up as a single-centre, double-blinded and randomized trial using
state of the art cardiac magnetic resonance imaging (MRI) to assess
infarct size, microvascular obstruction and cardiac remodelling, con-
firm ciclosporin blood level kinetics, and finally quantify lymphocyte
subset dynamics over 2 weeks from fresh blood samples. The results
of CAPRI should indicate why previous studies might have yielded a
negative result and provide information on potential targets for future
clinical trials.
2 | METHODS
2.1 | (please see online Supplemental methods for
additional information)
The CAPRI (‘Evaluating the effectiveness of intravenous ciclosporin
on reducing reperfusion injury in patients undergoing primary percu-
taneous coronary intervention’) trial (www.clinicaltrials.gov
NCT02390674, EudraCT number 2014–002628-29) was a single-cen-
tre, randomised, double-blinded, controlled trial of ciclosporin vs pla-
cebo (saline) in patients with acute myocardial infarction. The trial was
conducted in accordance with the principles of Good Clinical Practice
and received a favourable ethical opinion from the National Research
Ethics Committee North-East—Newcastle and North Tyneside
What is already known about this subject
Mitochondria are thought to be the critical mediator of
ischaemia reperfusion injury, and drugs that target the mito-
chondrial permeability transition pore have been successful
tested in a multitude of preclinical models. Two clinical trials
could not demonstrate a beneficial effect of the mitochon-
drial permeability transition pore inhibitor ciclosporin bolus
prior to myocardial reperfusion, but the mechanism is
unclear.
What this study adds
Intravenous administration of ciclosporin immediately
before primary coronary angioplasty is safe, but does not
affect myocardial injury, ventricular remodelling or
leucocyte kinetics. Serum levels of ciclosporin during reper-
fusion were 10-fold higher than established therapeutic
levels for immunosuppression, suggesting that either
(i) ciclosporin does not reach ischaemic cardiomyocytes, or
(ii) ciclosporin needs to be given at an earlier timepoint dur-
ing myocardial ischaemia (e.g. before transfer for primary
percutaneous coronary intervention). Also, 1 bolus of
ciclosporin is not sufficient to inhibit CD4 T-lymphocyte
proliferation during remodelling.
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2 (14/NE/1070) on 24 July 2014 and a clinical trial authorisation from
the Medicines and Healthcare products Regulatory Agency (MHRA)
on 9 September 2014. Recruitment occurred between March 2015
and November 2016. The trial was managed through the Newcastle
Clinical Trials Unit together with an independent Trial Steering Com-
mittee and Data Monitoring and Ethics Committee (DMEC). Monitor-
ing was performed by Newcastle Clinical Trials Unit and the trial was
audited by the sponsor, Newcastle upon Tyne Hospitals NHS Founda-
tion Trust and inspected by the MHRA. Following initial verbal con-
sent in the presence of an independent witness in the cathlab, written
informed consent was obtained from all patients after the PPCI
procedure/intervention.
2.2 | Study population
All participants had to present with an acute myocardial infarction
(STEMI) and undergo PPCI, be aged ≥18 years, and present within
6 hours of the onset chest pain. The culprit coronary artery had to be
a major coronary artery with a diameter of at least 3 mm and had to
be proximally occluded (TIMI flow grade 0–1) at the time of admission
coronary angiography.
Exclusion criteria for this trial were patients presenting with
immunological disorders, cardiogenic shock, unconscious patients, evi-
dence of coronary collaterals to the infarct area, open (TIMI>1) culprit
coronary artery at the time of angiography, previous myocardial
infarction or thrombolytic therapy, known renal or liver insufficiency,
uncontrolled hypertension (>180/110 mmHg), female patients cur-
rently pregnant or women of childbearing age who were not using
contraception (verbal diagnosis), or patients with contraindication to
cardiac MRI.
2.3 | Experimental protocol
Following angiography, participants were randomised in a 1:1 ratio to
either ciclosporin or control (saline) using a blocked allocation (per-
muted random blocks of variable length) system. Randomisation
included stratification by infarct location (anterior or nonanterior) and
sex. This was implemented using Newcastle Clinical Trials Unit's
online randomisation service. Ciclosporin (Sandimmun, Novartis) was
given as an intravenous infusion dissolved in saline (maximum concen-
tration 2.5 mg/mL) of 2.5 mg/kg of body weight (maximum total
amount 250 mg) through a catheter positioned within a peripheral
vein over 4 minutes. Trial medication was prepared by 2 unblinded,
Good Clinical Practice-trained research nurses according to local phar-
macy policy. After successful infusion, the coronary wire was
advanced and culprit lesion crossed, followed by revascularisation.
Primary outcome measure was infarct size at 12 weeks post-PPCI
as measured by cardiac MRI. Infarct size was calculated as the percent
of infarcted myocardium per left ventricular (LV) mass.
Secondary outcome measures included cardiac MRI (end-diastolic
volume [EDV], end-systolic volume [ESV], systolic volume, LV ejection
fraction (LVEF), myocardial mass [diastole/systole]), late gadolinium
enhancement outcomes at 2–7 days (baseline) and 12 weeks (micro-
vascular obstruction at baseline only, infarct size, myocardial mass),
change in T lymphocyte counts (B-cells [CD19], NK-cells, T-cells
[CD3] and CD4 and CD8 subtypes) relative to baseline at 5, 15,
30 and 90 minutes, and 24 hours postreperfusion. Additionally, we
also reported the number of clinical events (all cause death, stroke or
myocardial infarction) after 12 months. We additionally reported LV
remodelling, kinetics of lymphocyte populations and additional T-cell
subpopulations in posthoc analyses.
2.4 | Cardiac MRI
Cardiac MRI scans were obtained at 2–7 days as well as 12 weeks
post-myocardial infarction with a Siemens Avanto 1.5 Tesla MRI scan-
ner, using a phased array body coil combined with a spine coil. Intra-
venous gadobutrol contrast (Gadovist, Bayer Schering Pharma AG,
Berlin, Germany) was administered at a dose of 0.1 mmol/kg and,
after 10 minutes, short axis end-diastolic late gadolinium enhance-
ment images were obtained. All analysis was performed using vali-
dated cardiac MRI analysis software (cvi42, Circle Cardiovascular
Imaging Inc., Calgary, Canada) as previously described.16
2.5 | Statistical analysis
The primary endpoint, percentage infarct size post-PPCI (as measured
by cardiac MRI) was compared at 12 weeks between groups using the
2-sample t test. This analysis was then repeated using multiple linear
regression with adjustment for all stratification variables used during
the course of the trial (infarct location [anterior or nonanterior], sex
and time from symptom onset to randomisation [0 to <3 h or 3 to
≤6 h]). In light of the achieved sample size, and the publication of the
CONSORT extension guidelines for pilot trials,17,18 the study has pri-
marily been reported broadly in line with these, without formal
hypothesis testing of outcome measures other than a 12 week
between groups comparison of the primary outcome (percentage
infarct size post-PPCI as measured by cardiac MRI) using the
2-sample t test. Outcomes were summarised by group while addi-
tional, exploratory modelling is presented in supplemental tables.
3 | RESULTS
3.1 | Patient population
Out of 199 screened patients (Figure 1), 54 participants were rec-
ruited into the trial but only 52 were randomised to 1 of the 2 arms.
One participant was not included in the trial due to a problem encoun-
tered with viewing the allocation arm from the randomisation website
and the second was due to a technical problem with opening the pre-
scription. Participants were predominantly male, past or nonsmokers
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with little previous serious medical history or ongoing diabetes
(Table 1). Participants in the control arm were slightly older with the
median age being 66 years (interquartile range: 60.7–74.2) compared
to 61.3 years (interquartile range: 53.7–70.7) in ciclosporin arm. Over
2-thirds of patients had their infarct in the non-anterior location (69%
in each arm). Generally, all baseline characteristics were reasonably
well balanced between trial arms.
3.2 | Peri-interventional parameters
There were also no notable or apparent clinically important differ-
ences in peri-interventional characteristics (Table 2) between arms.
Time from symptom onset to reperfusion was around 3 hours in both
arms, and door-to-balloon time remained under 30 minutes despite
randomisation and trial drug infusion prior to reperfusion.
Periprocedural antiplatelet therapy (ticagrelor, prasugrel) was similar
in both arms, and TIMI 3 flow was achieved in 50 out of 52 patients.
Target vessel diameter and stented length were similar in both arms.
Discharge medication included dual antiplatelet therapy and atorva-
statin in all patients, and almost all patients received a β-blocker
(50/52) and an angiotensin converting enzyme inhibitor (49/52;
Table S1).
3.3 | Ciclosporin pharmacokinetics and safety
A full-time course of ciclosporin serum levels was determined in
10 randomly selected patients from the intervention arm, of whom
8 had a complete time course. Postreperfusion serum levels (at 5 min)
exceeded 4 mg/L, then quickly dropped to 0.2 mg/L at 90 minutes
and 0.02 mg/L 24 hours later (Figure 2A). In the Piot et al. study,
F IGURE 1 CONSORT diagram with
participant flow for each group, losses and
exclusions after randomisation
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ciclosporin concentrations were 6272 ± 714 ng/mL after 1 minute,
compared to ours (4068 ± 1254 ng/mL [4 mg/L]) after 5 minutes. We
both saw a sufficient blood concentration for at least 90–180 minutes
(therapeutic level 50–200 ng/mL). Following acute PCI, renal function
deteriorated in both groups, indicated by a rise in creatinine on day
3 (23% increase in control group vs 18% in ciclosporin group,
Table S1). However, there was no significant difference between
groups. Adverse events (AEs) occurred in 18 patients in placebo arm
(6 patients with ≥2 AEs), and 14 AEs in 11 patients in ciclosporin arm
(3 patients with ≥2 AEs). Finally, 23 contrast-induced nephropathy
AEs were classified as serious.
3.4 | Clinical endpoints
Few clinical events were observed in the trial at 12 months with just a
solitary death (caused by intracranial bleeding) and a nonfatal case of
stroke/cerebrovascular accident (chronic subdural haematoma)
TABLE 1 Baseline characteristics preadmission by arm
Control (n = 26) Ciclosporin (n = 26)
Categorical variables n (%) n (%)
Sex:
Male 20 77 24 92
Diabetes:
Yes 2 8 2 8
Smoking status:
Never 9 35 9 34.5
Past 12 46 9 34.5
Current 5 19 8 31
Medical history:
Ischaemic heart disease 0 0 3 11.5
Previous myocardial infarction 0 0 0 0
CVA/TIA 0 0 0 0
COPD 2 8 0 0
Peripheral vascular disease 1 4 0 0
Previous PCI 0 0 0 0
Other relevant history 6 23 11 42
Medication pre-admission:
Aspirin 4 15 1 4
Clopidogrel/prasugrel/ticagrelor 0 0 0 0
Beta-blocker 1 4 2 8
ACE inhibitor or angiotensin receptor blocker 2 8 6 23
Diuretic 3 11.5 1 4
Statin 6 23 6 23
Calcium channel blocker 4 15 3 11.5
Nitrates 0 0 1 4
Nicorandil 0 0 1 4
Infarct location:
Non-anterior 18 69 18 69
Anterior 8 31 8 31
Continuous variables n Median (IQR) Range n Median (IQR) Range
Age (y) 26 66.0 (60.7–74.2) 50.5–83.8 26 61.3 (53.7–70.7) 43.7–91.5
Body mass index 26 28.1 (24.1–31.7) 19.1–37.9 26 28.7 (24–31) 22.1–37.3
Time from symptom onset to
randomisation (min)
26 164 (120–227) 64–366 26 162 (94–272) 72–362
COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; IQR, interquartile range; PCI, percutaneous coronary intervention; TIA,
transient ischaemic attack.
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meeting the definition of a secondary outcome clinical event (death
from any cause, stroke or myocardial infarction). Both clinical events
occurred to participants in the ciclosporin arm after the end of the
12-week randomised controlled trial but before the final study follow-
up at 12 months. Other clinical events were observed in 3 participants,
which included angina and chest pain but these events were not
deemed to meet the definition of secondary outcome clinical events
in the trial).
TABLE 2 Peri-interventional characteristics by arm
Control (n = 26) Ciclosporin (n = 26)
Variable n (%) n (%)
Peri-interventional medication:
Aspirin 26 100 26 100
Clopidogrel 1 4 4 15
Prasugrel 21 81 19 73
Ticagrelor 4 15 3 11.5
Abciximab 0 0 1 4
Tirofiban 15 58 19 73
Bivalirudin 0 0 0 0
Heparin 26 100 26 100
Heparin units
≤5000 17 65.5 19 73
>5000 9 34.5 7 27
PCI-related parameters:
Culprit lesion
LAD 7 27 8 31
LCx 4 15 7 27
RCA 15 58 11 42
TIMI flow before
0 18 69 25 96
1 8 31 1 4
2 0 0 0 0
3 0 0 0 0
TIMI flow post
0 0 0 0 0
1 2 8 0 0
2 0 0 0 0
3 24 92 26 100
Aspiration catheter (y/n) 7 27 6 23
Reperfusion arrhythmias (y/n) 10 38.5 13 50
Continuous variables n Median (IQR) Range n Median (IQR) Range
PCI procedure:
Onset to balloon (min) 26 167.5 (107–241) 46–376 26 182 (116–287) 76–371
Call to balloon (min) 26 59.5 (50–79) 40–170 26 72 (51–90) 39–140
Door to balloon (min) 26 25.5 (23–33) 12–90 26 27 (22–33) 17–59
Onset of symptoms to reperfusion 26 175.5 (130–240) 69–380 26 189 (118–291) 72–371
Target vessel diameter (mm) 26 3.5 (3–3.7) 3–5 26 3.5 (3.5–4) 3–5
Target vessel stent length (mm) 26 33 (23–56) 0–89 26 37 (26–52) 7.5–114
Troponin T at admission (0 h; ng/L)* 26 46.5 (30–73) 12–799 26 58 (27–96) 7–1026
Troponin T at 12 h post PPCI (ng/L)* 26 3864 (1169–5659) 441–10 000 26 3414 (1190–6981) 333–10 000
*laboratory lists any troponin over 10000 as 10 000 exactly.
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3.5 | Effect of ciclosporin on infarct size and LV
remodelling
All 52 patients attended the 12-week follow-up visit for the cardiac
MRI, but in 4 patients (all from the intervention arm) 1 of their
2 MRI scans was not analysable (technical problems with scanner or
insufficient image quality, e.g. atrial fibrillation). The unadjusted mean
infarct size at 12 weeks was identical in both arms (mean = 9.1,
standard deviation [SD] = 7.0, Figure 2B), and when the distribution
of covariates was taken into account, there was still little or no dif-
ference in mean percentage infarct size between arms (adjusted
mean difference of −0.1 (95% confidence interval [CI] −2.4 to 2.2).
While the 95% CIs are wide, they do not extend beyond the clini-
cally important difference of 4.6% used to establish the sample size.
The absolute reduction of 5% deemed to be of clinically important
significance19 was also not observed. Finally, we looked at LV
remodelling, comparing the 12-week MRI scans to the baseline MRI
scans (Table 3). There was a nonsignificant reduction in infarct size
in both treatment arms (2.4 vs 1.8%), probably owing to discrete
overestimation at baseline secondary to myocardial oedema.20,21
LVEF appeared to improve in both arms at 12 weeks from baseline,
and may have been greater improvement in control arm than inter-
vention arm (6.8% (SD = 7.6) vs 2.1% (SD = 8.8), Table 3 and
Table S4). While a change in EDV is important for remodelling, only
changes in ESV appeared to correlate with ΔLVEF (r = −0.77,
Figure 2C,D). Hence, LV volumes appeared to be more reduced in
the control arm, especially difference for ESV (ΔESV −12.2
vs +1.4 mL; ΔEDV −2.0 vs +9.1 mL, Table S3).
3.6 | Lymphocyte kinetics in myocardial
ischaemia/reperfusion
To elucidate the impact of a single ciclosporin bolus on a proximal
readout, each continuous secondary outcome was compared at base-
line between arms or at short snapshots in time as appropriate (0–90
min, 24 h). A statistically significant change in T lymphocyte counts
(CD3) between arms was only observed at 5 minutes relative to
baseline but this effect was no longer present from 15 minutes
onwards (Tables S4a-g). The unadjusted mean CD3 counts were not
F IGURE 2 Ciclosporin does not affect cardiac remodelling post infarction. (A) Ciclosporin serum level kinetics for n = 8 randomly selected
patients from ciclosporin group (displayed as mean ± standard error of the mean per time point). (B) Infarct size after 3 days and 12 weeks. (C, D)
correlation of changes in left ventricular ejection fraction (LVEF), end-diastolic volume (EDV) and end-systolic volume (ESV) in 48 patients with
both magnetic resonance images (Spearman r)
CORMACK ET AL. 7
T
A
B
L
E
3
C
ar
di
ac
m
ag
ne
ti
c
re
so
na
nc
e
im
ag
in
g
an
d
la
te
ga
do
lin
iu
m
en
ha
nc
em
en
t
da
ta
at
ba
se
lin
e
an
d
1
2
w
ee
ks
by
ar
m
C
o
nt
ro
l
C
ic
lo
sp
o
ri
n
B
as
el
in
e
1
2
w
ee
ks
B
as
el
in
e
1
2
w
ee
ks
O
ut
co
m
e
n
M
ed
ia
n
(IQ
R
)
R
an
ge
n
M
ed
ia
n
(IQ
R
)
R
an
ge
n
M
ed
ia
n
(IQ
R
)
R
an
ge
n
M
ed
ia
n
(IQ
R
)
R
an
ge
In
fa
rc
t
si
ze
(%
)
2
5
1
0
(7
.1
–1
5
.3
)
0
.9
–5
4
.7
2
3
9
.1
(3
–1
3
.9
)
0
–2
8
.2
2
6
9
.5
(2
.9
–1
4
.5
)
0
.2
–3
6
.8
2
6
9
.8
(4
.2
–1
1
.4
)
0
–2
7
.2
M
yo
vo
l(
m
L)
2
5
1
2
3
.5
(1
0
2
.4
–1
4
7
.7
)
7
9
.6
–2
2
5
.6
2
3
1
0
5
.8
(8
9
.4
–1
1
1
.7
)
6
3
–1
4
5
.2
2
6
1
3
3
.5
(1
1
3
.5
–1
4
4
)
7
4
.8
–1
8
2
.9
2
6
1
1
1
.5
(9
7
–1
2
7
.4
)
5
4
.2
–1
4
6
.6
M
yo
m
as
s
(g
)
2
5
1
2
9
.6
(1
0
7
.5
–1
5
5
.1
)
8
0
.7
–2
3
6
.9
2
3
1
1
1
.1
(9
3
.9
–1
1
7
.3
)
6
6
.1
–1
5
2
.4
2
6
1
4
0
.1
(1
1
9
.2
–1
5
1
.2
)
7
8
.5
–1
9
2
.1
2
6
1
1
7
.1
(1
0
1
.9
–1
3
3
.8
)
5
6
.9
–1
5
4
In
fa
rc
t
vo
l(
m
L)
2
5
1
1
.8
(7
.6
–2
0
.5
)
0
.9
–6
6
.5
2
3
8
.2
(2
.9
–1
5
.2
)
0
–3
0
.1
2
6
1
2
.0
(2
.3
–2
1
.3
)
0
.2
–5
4
.8
2
6
1
0
.0
(4
.3
–1
4
.1
)
0
–3
8
.2
In
fa
rc
t
m
as
s
(g
)
2
5
1
2
.3
(8
–2
1
.6
)
0
.9
–6
9
.8
2
3
8
.6
(3
–1
6
)
0
–3
1
.6
2
6
1
2
.6
(2
.4
–2
2
.4
)
0
.2
–5
7
.6
2
6
1
0
.4
(4
.5
–1
4
.8
)
0
–4
0
.1
M
V
O
m
as
s
(g
)
2
5
0
.2
(0
–1
.6
)
0
–1
7
.9
N
A
N
A
2
6
0
(0
–0
.4
)
0
–3
2
.4
N
A
N
A
E
D
V
(m
L)
2
5
1
5
6
.6
(1
3
7
.7
–1
7
3
.8
)
1
0
3
.9
–2
2
5
.8
2
3
1
5
3
.5
(1
3
6
.1
–1
7
1
.5
9
2
.6
–2
4
0
.7
2
6
1
6
1
.9
(1
4
0
.9
–1
7
8
.1
)
1
1
5
.8
–1
9
5
.5
2
6
1
7
3
.9
(1
4
7
.3
–1
9
3
.5
)
1
0
3
–2
3
8
.8
E
SV
(m
L)
2
5
8
0
.9
(6
8
–9
1
.3
)
4
0
.7
–1
5
2
.2
2
3
6
7
.8
(4
9
.6
–8
5
.8
)
2
6
.6
–1
2
0
.4
2
6
7
5
.4
(6
7
.8
–9
7
)
3
8
–1
1
3
.2
2
6
7
5
.6
(6
0
.3
–9
5
.4
)
3
5
.5
–1
6
0
.9
SV
(m
L)
2
5
7
6
.6
(6
3
.2
–8
5
.8
)
3
1
.9
–1
0
5
.8
2
3
8
4
.3
(7
2
.4
–9
4
.7
)
5
0
.6
–1
2
1
.1
2
6
8
0
.2
(6
9
.8
–8
9
.2
)
5
9
.5
–1
1
1
.7
2
6
8
2
.6
(7
4
.7
–1
0
3
.5
)
5
4
–1
1
9
.9
LV
E
F
(%
)
2
5
4
9
.2
(3
8
.5
–5
6
.5
)
2
5
.6
–6
6
.8
2
3
5
5
.1
(4
8
.7
–6
4
.2
)
3
5
.5
–7
1
.2
2
6
5
3
.5
(4
4
.1
–5
6
.9
)
3
6
.5
–6
7
.8
2
6
5
3
.2
(4
9
–6
0
.7
)
3
2
.6
–6
5
.5
M
yo
m
as
s
di
as
to
le
(g
)
2
5
1
0
7
.8
(8
6
.5
–1
1
8
.5
)
6
7
.5
–2
0
3
.5
2
3
9
1
.8
(8
1
.1
–1
0
5
.2
)
5
8
.1
–1
3
4
.5
2
6
1
1
3
.9
(1
0
5
.7
–1
3
5
.2
)
7
6
.2
–1
6
2
.6
2
6
1
0
1
.2
(8
1
.9
–1
1
4
.5
)
6
1
.3
–1
3
2
.5
M
yo
m
as
s
sy
st
o
le
(g
)
2
5
1
1
3
.1
(9
2
.5
–1
2
1
.1
)
6
8
.8
–2
0
1
.3
2
3
9
8
.7
(8
5
.4
–1
0
7
.5
)
5
9
.9
–1
3
7
.5
2
6
1
1
9
.9
(1
0
9
.6
–1
3
6
.7
)
7
8
.8
–1
8
0
.8
2
6
1
0
8
.4
(8
5
.4
–1
2
5
.8
)
5
5
.6
–1
5
6
.7
8 CORMACK ET AL.
significantly higher in the ciclosporin arm at 5 minutes compared to
the control arm, but when the distribution of covariates were taken
into account they were significantly higher in the ciclosporin arm
(adjusted mean difference of 142.4 [95% CI: 23.9 to 260.9] Tables S5
and S6). The mean drop (relative to prereperfusion) of CD3 T-
lymphocytes at 90 minutes was 26% in the control arm vs 37% in the
ciclosporin arm. At 24 hours (Table S6) and 2 weeks postreperfusion,
there was no statistical difference between control and ciclosporin
arm for CD4 T-cells, CD8 T-cells, natural killer cells, and B-lympho-
cytes, suggesting no antiproliferative effect of ciclosporin bolus on
any lymphocyte population.
4 | DISCUSSION
The results of the CAPRI pilot trial, as did the recently reported
CYCLE and CIRCUS multicentre trials, add further evidence to the
lack of effect of ciclosporin on myocardial ischaemia/reperfusion
injury in patients with acute STEMI. This suggests that mitochondrial
pore inhibition by ciclosporin or similar drugs does either not reach
ischaemic cardiomyocytes or requires earlier application. Alternatively,
it is possible that in this era with stent-based revascularisation under
optimal antiplatelet therapy myocardial ischaemia/reperfusion injury
is clinically less relevant than previously thought.11 Almost all of the
CAPRI patients received either ticagrelor or prasugrel in addition to
aspirin prior to reperfusion. These results are a further indication that
translation of successful animal studies into the clinic is far from
straight forward, probably because of the nature of experimental
models. None of these studies so far has been able to model plaque
rupture with thrombotic load and a comparable response of the adap-
tive immune system.
While previous trials have considered some of the methodological
issues, we have addressed the following matters: (i) a fully blinded
(and not open-label), randomised design; (ii) confirmed optimal drug
concentration and pharmacokinetics; (iii) used cardiac MRI imaging
with gadolinium contrast as a gold-standard rather than echocardiog-
raphy to quantify acute infarct size; (iv) performed a second MRI at
3 months to quantify remodelling as well as late infarct size; and
finally (v) used polychromatic flow cytometry to meticulously docu-
ment the time course of all major lymphocyte subsets during reperfu-
sion and 2-week recovery, given that CX3CR1-dependent T-
lymphocyte marginalisation coincides with microvascular obstruction
and determines long term mortality in these patients.16
4.1 | LV remodelling post-STEMI
Despite not finding evidence of a statistical or clinically meaningful
difference in the primary outcome, the design of the CAPRI trial
enabled us to look at additional parameters in order to capture fur-
ther effects of ciclosporin, if existent. CAPRI is the largest MRI
ciclosporin trial to quantify infarct size as well as LV remodelling. To
our surprise, despite identical scar size at 12 weeks post-MI,
remodelling in the control trial arm appeared more favourable than
in the ciclosporin arm. This appeared to be driven by the higher
number of TIMI 1 patients prereperfusion. A reduction in ESV, but
not EDV, appeared to be the main determinant of improved LV func-
tion after 12 weeks. Unlike CAPRI, CYCLE was an open label trial
and CIRCUS used a different formulation of ciclosporin. In addition,
neither of the 2 previous studies used cardiac MRI to assess their
endpoints. Two-dimensional echocardiography without the use of a
contrast dye is not able to quantify infarct size, and it is the least
accurate method to determine LV volumes. The raw data of the
CYCLE and CIRCUS trial also show that LV volumes in a similar
patient population differ by almost 100% between these 2 studies,
possibly due to different formulas to estimate LV volumes. The CIR-
CUS trial has looked at remodelling purely based on 2-dimensional
echocardiography without ultrasound contrast (Simpson formula).
Measurements of LVEF by 2-dimensional echocardiography have
been tarnished by significant observer variability and poor agreement
with reference methods.22-24 LV opacification by intravenous ultra-
sound contrast agents improves both.25
4.2 | T-cell response and ciclosporin in STEMI
The role of T-lymphocytes in infarct healing post STEMI has not been
investigated before in clinical trials26,27; however, Weirather and col-
leagues have previously demonstrated the role of regulatory T-cells in
the remodelling process in a mouse model.28 The Frangogiannis group
has also identified in the mouse that CCR5 signalling suppresses
inflammation and reduces adverse remodelling of the infarcted heart,
mediating recruitment of regulatory T cells.29 We have previously
shown that the magnitude of the proinflammatory Th1 response from
CD4 T-cells in acute STEMI patients correlates with total ischaemic
time.30 We also identified a proliferative response among CD4 T-cells
during the first 24 hours postreperfusion,31 which has now been con-
firmed in the CAPRI trial (Online Table 4a-g). While in vitro experi-
ments demonstrate that differentiation from naïve into Th1 cells is
inhibited by ciclosporin,32,33 the CAPRI trial did not identify an antip-
roliferative effect of ciclosporin during the first 24 hours, despite
pharmacologically relevant serum levels during the first hours follow-
ing bolus application.
4.3 | Alternative mechanism and timing for
ciclosporin therapy in STEMI
One of the reasons why ciclosporin did not demonstrate additional
protection could have been the co-medication with ticagrelor,34-36
prasugrel or ACE inhibitors,37,38 which have all demonstrated
favourable effects in patient outcome by themselves. Many of our
patients have call to balloon times of over an hour despite short door
to balloon times. Especially when patients are admitted to an emer-
gency room in a noninterventional hospital, interhospital transfer adds
a significant delay to successful reperfusion. In this trial all patients
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had ciclosporin been given immediately (5 min) before successful
reperfusion. It is possible that ciclosporin is not so effective for reper-
fusion injury (which is not a proven phenomenon in human patients),
but rather in ischaemic cardiomyocytes and endothelial cells,
preventing or delaying ongoing apoptosis in those cell types.
Ciclosporin (10 μmol/L) completely inhibited the oxLDL-induced
release of cytochrome C in a study by Walter and colleagues.39 More-
over, tumour necrosis factor-α- and angiotensin II-induced cyto-
chrome C release was also prevented by ciclosporin treatment. There
is a clinical window of at least 60 minutes in most STEMI patients
where, other than pain medication and aspirin, basically no therapy is
present. Application of ciclosporin 60 minutes before reperfusion
could have a significant effect on infarct size, if it prevents car-
diomyocyte or endothelial cell apoptosis in vivo at the given
concentration.
5 | CONCLUSIONS
We confirm in this clinical trial that intravenous administration of the
mitochondrial pore inhibitor ciclosporin before reperfusion by primary
coronary angioplasty is safe, but does not affect myocardial injury.
Serum levels of ciclosporin during 90 minutes of reperfusion were
10-fold higher than established therapeutic levels for immunosuppres-
sion, suggesting that either (i) ciclosporin does not reach ischaemic
cardiomyocytes, or (ii) ciclosporin needs to be given at an earlier time-
point during myocardial ischaemia (e.g. before transfer for primary
PCI). Also, 1 bolus of ciclosporin is not sufficient to inhibit CD4 T-
lymphocyte proliferation during remodelling. Given that ciclosporin is
safe in STEMI patients, we suggest conducting a new randomised
controlled trial where ciclosporin is given at the first point of contact
(e.g. ambulance) and also test prolonged therapy in order to inhibit T-
cell proliferation during remodelling.
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